Emtricitabine/Tenofovir disoproxil Zentiva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
WS/2486 
This was an application for a variation following a 
09/11/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
SmPC, Annex 
II and PL 
authorisation, including the RMP - Other variation 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/05/2023 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0023 
A.4 - Administrative change - Change in the name 
09/06/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0022 
B.II.e.2.z - Change in the specification parameters 
29/11/2021 
n/a 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IB/0021/G 
This was an application for a group of variations. 
10/09/2021 
n/a 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
R/0019 
Renewal of the marketing authorisation. 
20/05/2021 
16/07/2021 
SmPC, Annex 
II, Labelling 
and PL 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
24/03/2021 
16/07/2021 
SmPC, Annex 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
II, Labelling 
and PL 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/01/2021 
09/03/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
II/0015 
B.I.a.1.b - Change in the manufacturer of AS or of a 
03/12/2020 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IA/0017 
B.II.b.3.a - Change in the manufacturing process of 
22/10/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0016 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
16/03/2020 
09/03/2021 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IB/0014/G 
This was an application for a group of variations. 
08/08/2019 
03/09/2019 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
II, Labelling 
and PL 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0012/G 
This was an application for a group of variations. 
06/07/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IA/0013/G 
This was an application for a group of variations. 
14/06/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0010 
C.I.11.z - Introduction of, or change(s) to, the 
13/06/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0011 
B.I.b.2.a - Change in test procedure for AS or 
29/04/2019 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0009 
B.II.b.1.a - Replacement or addition of a 
25/03/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0008 
B.I.a.1.a - Change in the manufacturer of AS or of a 
12/03/2019 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IAIN/0007/G 
This was an application for a group of variations. 
16/01/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0005/G 
This was an application for a group of variations. 
20/12/2018 
23/01/2019 
SmPC, 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/1029 
A.5.b - Administrative change - Change in the name 
18/12/2018 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0004 
B.I.a.3.a - Change in batch size (including batch size 
13/09/2018 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
C.I.11.z - Introduction of, or change(s) to, the 
08/01/2018 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0002/G 
This was an application for a group of variations. 
14/09/2017 
13/10/2017 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
II/0001 
B.I.z - Update of Tenofovir disoproxil phosphate DMF 
27/04/2017 
n/a 
no. EU/ASMF/00052 with the addition of a new 
intermediate active substance manufacturer. 
B.I.z - Quality change - Active substance - Other 
variation 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
